Background. To identify changes in patient presentation, treatment, and outcomes of low-grade gliomas (LGGs) over the past 50 years. Methods. Records of 852 adults who received a diagnosis at Mayo Clinic from 1960 through 2011 with World Health Organization grade II LGGs were reviewed and grouped by those who received a diagnosis before (group I: 1960 -1989 ) and after (group II: 1990 -2011) the routine use of postoperative MRI. Results. Median follow-up was 23.3 and 8.7 years for groups I and II, respectively. Patients in group I more often presented with seizures, headaches, sensory/ motor impairment, and astrocytoma histology. Over time, more gross total resections (GTRs) were achieved, fewer patients received postoperative radiotherapy (PORT), and more received chemotherapy.
Median progression-free survival (PFS) and overall survival (OS) were 4.4 and 8.0 years, respectively. Although PFS was similar, 10-year OS was better in group II (47%) than in group I (33%; P , .0001). Improved PFS in multivariate analysis was associated with group I patients, nonastrocytoma histology, small tumor size, successful GTR, or radical subtotal resection (rSTR), PORT, and postoperative chemotherapy. Factors associated with improved OS in multivariate analysis were younger age, nonastrocytoma histology, small tumor size, and GTR/ rSTR. Conclusions. OS for LGG has improved over the past 50 years, despite similar rates of progression. In the modern cohort, more patients are receiving a diagnosis of oligodendroglioma and are undergoing extensive resections, both of which are associated with improvements in OS. Because of risk factor stratification by clinicians, the use of PORT has decreased and is primarily being used to treat high-risk tumors in modern patients.
Keywords: central nervous system tumors, externalbeam radiotherapy, low-grade glioma, neurosurgery, oligodendroglioma. L ow-grade gliomas (LGGs) are World Health Organization (WHO) grade I or II tumors typically seen in children and young adults. 1 Adult LGG is an uncommon entity for which prognostic factors have not been clearly established, and relatively few randomized clinical trials are available to guide treatment decisions. 2 The optimal role and timing of radiotherapy (RT) has been evaluated in one prospective trial; 3, 4 however, there is no established consensus for its use in the oncology community.
The only prospective study, European Organization for Research and Treatment of Cancer (EORTC) 22845, found that progression-free survival (PFS) but not overall survival (OS) was improved with immediate postoperative RT (PORT). 3, 4 Our group previously conducted a retrospective study of adult patients with WHO grade II LGG diagnosed at Mayo Clinic from 1960 through 1992 that confirmed the PFS and OS benefit of extensive surgical resection and found improved PFS and OS with PORT after incomplete resections. 5 A similar analysis of patients who received a diagnosis from 1992 through 2011 again confirmed the PFS and OS benefit of surgical resection and the PFS benefit of PORT in patients with incomplete resections.
However, PORT was associated with lower OS, possibly because of risk factor stratification, with only the highest-risk patients receiving PORT.
Over the past 50 years, many changes to the diagnosis and treatment of LGGs have taken place. Computed tomography (CT) was integrated into clinical practice in the 1970s, and by the early 1990s at Mayo Clinic, postoperative MRI was integrated into the routine management of adult LGG. 7 In the present study, we further investigate controversial topics in adult LGG with an updated follow-up to our prior reports. The goal of this study was to evaluate changes in prognostic factors, treatment indications, and outcomes in adult patients with LGG over the past 50 years.
Materials and Methods
Records from 852 adults who received a diagnosis of LGG at Mayo Clinic from 1960 through 2011 were reviewed. Patients included were at least 18 years of age, with a WHO grade II glioma confirmed by a Mayo Clinic neuropathologist. Patients with neurofibromatosis type 1 were excluded. Patients were grouped by those who received a diagnosis before (group I: 1960 -1989 ) and after (group II: 1990 -2011) the routine use of postoperative MRI in adult LGGs at Mayo Clinic.
The extent of surgical resection was determined by postoperative imaging and operative reports if imaging was not available. The definition of gross total resection (GTR) was no evidence of remaining tumor after excision. Radical subtotal resection (rSTR) was defined as .90% of the tumor removed with some residual tumor present postoperatively. Surgical procedures with ,90% of the tumor removed after debulking were classified as subtotal resection (STR). If tissue was solely obtained for diagnosis without debulking, the procedure was classified as biopsy only (Bx).
Grading of tumors was performed in accordance with WHO standards and was recorded retrospectively from original pathology reports. 1 This study excluded all WHO grade I tumors. Grade II tumors included in this study were diffuse and gemistocytic astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. Disease progression was determined by clinical assessment, imaging reports, pathology studies, or other additional tumor-directed therapies. The Mayo Clinic Institutional Review Board approved this study. Since 2003, 1p/19q status was routinely assessed using fluorescent in situ hybridization in oligodendrogliomas and oligoastrocytomas.
Statistical Analysis
Assessment of prognostic factors related to OS and PFS was performed using univariate and multivariate analyses. Factors were chosen on the basis of importance in previous studies. 2, 3, 5, 8, 9 The Kaplan-Meier method was used to construct PFS and OS curves that were compared using the log-rank test. Multivariate analysis used the Cox proportional hazards model. Patients who died without documented recurrence were censored for recurrence at the time of death. This approach assumes that those with unknown disease status at death or last contact died of disease. All statistical significance tests performed were 2-tailed. The x 2 test and Fisher's exact test were used to assess relationships between prognostic factors and extent of surgery or postoperative RT.
Results

Initial Patient Presentation
Characteristics between the groups studied are summarized in Table 1 . More patients in group I had multiple symptoms present at diagnosis than in group II (51% vs 24%; P , .0001). Only 11 patients were asymptomatic at diagnosis, and all were in group II. Eight of those (73%) had their tumor discovered incidentally on head imaging for an unrelated condition, most commonly after a motor vehicle accident. Patients in group II had more oligodendrogliomas (34% vs 10%), more oligoastrocytomas (44% vs 31%), and fewer astrocytomas (22% vs 59%), compared with group I (P , .0001; Fig. 1A ).
Surgical Trends
In group II, more GTRs (31% vs 13%) and fewer STRs were performed (21% vs 42%). Rates of rSTR and Bx were similar between the groups. When available, postoperative imaging was used to define the extent of surgery, even in cases where it differed from the neurosurgeon's intra-operative impression. In a subset of patients who received a diagnosis during or after 1993, postoperative imaging was available for 70% and was concordant with the neurosurgeon's impression in 98% of cases. The discordant cases were rSTRs identified by postoperative imaging that were overestimated as GTRs intraoperatively. 6 Overall, patients undergoing successful GTR/rSTR were at lower risk, ≤40 years of age, with nondeep tumors, size , 5 cm, nonastrocytoma histology, and no speech, sensory, or motor symptoms (all P , .05). Trends in surgical interventions are shown by decade in Fig. 1B .
Postoperative Interventions
Factors associated with PORT are shown in Table 2 , and trends by decade are shown in Fig. 1C . In group II, fewer patients received PORT (58% vs 74%; P , .0001), and more received chemotherapy (18% vs 6%; P , .0001), compared with group I. In both groups, PORT was preferentially delivered to those receiving STR/Bx (P , .0001). However, in group II, additional factors associated with PORT included astrocytomas (P ¼ .003), tumors ≥5 cm (P ¼ .0003), deep location (P , .0001), and age .40 years (P , .0001). The median dose of RT was 5400 cGy for both groups. The ranges of doses used were 2850 -7020 cGy for group I and 4500 -7200 cGy for group II, which is shown by decade in Fig. 1D .
Tumor Progression
Overall, 498 patients (59%) had tumor progression, including 159 in group I and 339 in group II. Median PFS was 4.4 years for the entire cohort. Ten-year PFS was 22%, which was similar between group I and group II (25% vs 20%; P ¼ .08) ( Fig. 2A) . In the 133 patients with 1p/19q data, better median PFS was seen in 1p/19q codeleted tumors (5.0 vs 2.8 years; P , .0001).
Patients receiving GTR and rSTR had no statistically significant difference in PFS and were grouped together for analysis. In addition, STR and Bx were not different and were similarly grouped together for analysis. Overall, 10-year PFS was better among patients undergoing GTR/rSTR (34%) than among those receiving STR/ Bx (16%; P , .0001) (Fig. 2B ). This was replicated in analysis of group I and group II individually (both P , .0001).
In univariate analysis, PORT did not improve PFS overall (P ¼ .41) or in group I or II individually (both P . .05). However, 10-year PFS was improved with PORT in patients receiving STR/Bx (20% vs 2%; P , .0001) (Fig. 2C) . This was conserved with individual analysis of group I and group II (both P , .0001). There was no difference in PFS between patients receiving at least 54 Gy and those receiving ,54 Gy (P ¼ .24).
Postoperative chemotherapy did not influence PFS overall or in individual analysis of group I and group II (all P . .05). PFS was improved, however, with postoperative chemotherapy in patients receiving STR/Bx (27% vs 14% at 10 years; P ¼ .03). Of (Table 3) for the entire cohort included group I patients, nonastrocytoma histology, tumors ,5 cm, successful GTR/rSTR, PORT, and postoperative chemotherapy. When analyzed by group, size, extent of resection, and PORT remained significantly associated with improved PFS in both groups. Younger age was additionally associated with improved PFS in group I. Histology and postoperative chemotherapy remained significantly associated with improved PFS only in group II. When patients with seizures were separated by those with accompanying neurological symptoms and those with seizures alone, neither group was statistically significantly associated with PFS in multivariate analysis.
Survival Trends
As of last follow-up, 168 patients were alive without evidence of tumor, 172 were alive with persistent tumor, and 22 were alive with unknown tumor status. A total of 490 (58%) deaths were recorded: 246 in group I and 244 in group II. Of the patients who died, 332 died of tumor progression, 4 died with no evidence of disease, and 154 died but were lost to follow-up before their death, and consequently, their disease status is unknown. There were 4 (,1%) deaths possibly related to radiation necrosis, although recurrence as a higher-grade necrotic tumor is possible. Median OS was 8.0 years for the entire cohort, which was better in group II than in group I (9.3 vs 6.2 years; P , .0001) (Fig. 3A) . Overall, patients undergoing GTR/rSTR had better OS (10-year, 60%) than did those receiving STR/Bx (33%; P , .0001) (Fig. 3B) . This was replicated in subgroup analysis of group I (53% vs 27%; P ¼ .0002) and group II (62% vs 39%; P , .0001). Median OS was better in 1p/19q codeleted tumors (14.3 vs 5.9 years; P ¼ .0001).
Multivariate analysis of prognostic factors for OS is shown in Table 3 . Neither PORT nor chemotherapy was associated with improved OS overall. Factors associated with improved OS in multivariate analysis overall were younger age, nonastrocytoma histology, tumor size ,5 cm, and GTR/rSTR. Smaller tumor size, GTR/ rSTR, and use of PORT were statistically significant in multivariate analysis of group I. Factors associated with better OS in multivariate analysis of group II included younger age, nonastrocytoma histology, GTR/rSTR, and not receiving PORT. As was seen with seizure-related subgroups (seizures alone vs seizures with neurological symptoms) in multivariate PFS analysis, there was no statistically significant association with OS in multivariate analysis.
Treatment of Progression
In the 498 patients with documented progression, 149 (30%) received RT, 285 (57%) received chemotherapy, 191 (38%) underwent surgery, and 42 (8%) were observed at progression. Because of treatment at another institution, progression was diagnosed but treatment specifics were not available in 54 patients (11%).
Surgical resection for recurrent disease was associated with improved OS (median, 7.6 vs 6.6 years; P ¼ .02) and survival from the date of recurrence (SFR; median, 2.4 vs 1.7 years; P ¼ .003). Treatment of recurrence with RT was associated with improved OS (9.2 vs 6.3 years; P ¼ .0005) and SFR (5.2 vs 1.5 years; P , .0001). Compared with patients receiving PORT, 10-year OS was better among those able to delay RT until recurrence (57% vs 37%; P ¼ .0008). Chemotherapy at recurrence was associated with improved OS (7.6 vs 5.9 years; P ¼ .02) and SFR (2.6 vs 1.4 years; P ¼ .001).
Discussion
This study analyzed changes in presentation, treatment, and outcomes of adult LGG over the past 50 years. In the modern cohort at Mayo Clinic, fewer patients were symptomatic at initial presentation, more were receiving a diagnosis of oligodendrogliomas, the rate of successful GTR/rSTR had increased, and the use of PORT had decreased. These changes are seen in the context of improved OS over the past 50 years, despite similar rates of progression.
Patients in group I often had multiple concurrent symptoms at presentation, which was less common in group II. This was likely attributable to earlier access to Abbreviations: GTR, gross total resection; PORT, post-operative radiotherapy; rSTR, radical subtotal resection; WONS, with other neurological symptoms. modern neuroimaging in the diagnostic evaluation of seizures, headaches, or neurological dysfunction than was previously available. This is particularly relevant for seizures, which now represent the unique symptom at presentation in a vast proportion of patients with LGGs. 10 Although seizures as the sole presenting symptom have been associated with improved prognosis, 11 no such relationship was found in this study. Increased access to modern imaging also introduces the possibility of incidentally discovered asymptomatic tumors. This was a rare finding restricted exclusively to group II, typically found during a trauma evaluation after a motor vehicle accident.
Our report of age, histology, and size as prognostic factors for OS is consistent with prior studies. 12 -14 In addition, the extent of surgical resection was significantly associated with OS, consistent with several prior reports, 2, 14, 15 yet inconsistent with the EORTC prognostic factors reported by Pignatti et al. and confirmed by Daniels et al. in 2011. 13, 16 We found that the extent of surgical resection was associated with many of the prognostic factors reported by Pignatti et al., including age, tumor size, histology, and preoperative neurological deficit. In addition, advances in neurosurgery (e.g., intraoperative mapping and awake surgery) have increased the likelihood of GTR in tumors near critical areas. 17 Although it has been suggested that the impact of extensive surgical excision on prognosis may be confounded by tumor size and location, 13 this was not true for our cohort. Unfortunately, many patients with LGG are unable to undergo GTR/rSTR, and RT is frequently offered postoperatively. The controversial role of RT in adult LGG has been studied by only a few prospective trials. EORTC 22845 was a phase III trial of 311 adult patients with LGG treated with surgery and randomized to observation or PORT (54 Gy). 3, 4 The authors reported significantly improved 5-year PFS among patients receiving PORT (55% vs 35%). Possibly because patients in the observation arm were treated with RT after tumor progression in EORTC 22845, no significant difference in OS was seen between the 2 treatment arms. The current study also found no OS benefit overall with PORT, consistent with EORTC 22845. Also consistent with EORTC 22845, PORT was associated with significantly improved PFS in multivariate analysis and appears to be of greatest benefit to those undergoing STR/Bx.
Although the vast majority of patients in group I received PORT, it was delivered in a more selective fashion in group II. This may explain the association between PORT and improved OS seen in multivariate analysis of group I, along with the opposite association in group II. Older patients, those with deep tumors, and those with astrocytomas commonly received PORT in group II but not in group I. In both groups, STR/Bx was associated with delivery of PORT. This selectivity highlights changing attitudes toward the role of PORT in adult LGG in recent years. Because of our very low incidence of radiation necrosis (,1%), the association between PORT and lower OS in multivariate analysis of group II is likely attributable to additional risk factors not taken into account by our multivariate model (e.g., performance status) rather than to a true detrimental effect. Of note, it is possible that the lack of improvement in PFS overall in group II compared with group I, despite improving OS, may be a reflection of the decrease in the use of PORT.
The present study found no association overall between improved OS and PORT in multivariate analysis. This finding, along with the lack of a survival benefit reported in EORTC 22845, may lead clinicians to delay RT until progression. This may be appropriate in some subgroups of patients; however, this should not be a universal approach because of the clear PFS benefit, particularly in symptomatic high-risk patients. The fear of RT-related adverse effects, including cognitive dysfunction, may further influence clinical decision-making. Both tumor progression and RT may potentially result in neurocognitive decline, and the risk of imminent neurologic deterioration must be weighed against the possibility of long-term neurocognitive decline. 18 -21 Although the cognitive effects of PORT are controversial, there appears to be little risk of RT-related neurocognitive decline until after 10 years. 18,22 -24 Thus, we recommend the use of PORT in patients at high risk of early progression, which includes those with astrocytomas, large tumors, and/or incomplete resections. In these patients, progression may be further delayed by adding chemotherapy to PORT. 25 On the other hand, solely using chemotherapy postoperatively may be a reasonable alternative for large tumors requiring sizable RT fields in patients with expected survival .10 years, who consequently may be at risk of late neurotoxicity. 26 The changing proportions of oligodendrogliomas could represent differences in pathological diagnostic criteria over the past 50 years. Significant interobserver variation has been established as a potential weakness of glioma studies. 27 However, these changing proportions are not unique to our institution, as recent Surveillance, Epidemiology and End Results data reported a similar trend. 28 In addition, our survival trends were consistent with the reported histology, with better OS seen in oligodendrogliomas than in astrocytomas. Our 5-year OS of 82% with oligodendrogliomas is comparable to survival reported by Shaw et al. in 2002 (5-year OS, 74% for oligopredominant tumors). 9 Thus, although the proportion of oligodendrogliomas has clearly changed over time, the pathologic classification appears to accurately reflect prognosis.
In addition to its retrospective design, this study has several important limitations. Although incidentally discovered asymptomatic tumors were rare, the improved OS seen in the modern cohort may reflect lead-time bias from earlier diagnosis with modern imaging. One of the most significant limitations is our lack of long-term quality of life (QOL) and toxicity data. An important finding of this study is the lack of improvement in PFS over time despite improving OS. In the literature, few data exist to assess the impact of radiographic tumor progression on QOL, cognitive function, seizure control, and functional status in such patients. The currently open Radiation Therapy Oncology Group (RTOG) phase II trial, RTOG 0925, will assess neurocognitive function, QOL, and seizure control over time in low-risk patients with newly diagnosed LGG undergoing observation postoperatively. As a secondary end point of the study, clinical, neurologic, and radiographic progression will be correlated with QOL and cognitive function to try to determine a more clinically meaningful definition of progression. Another limitation of this study includes missing information because of the nature of data collection. For example, tumor size was not available in 47%, and contrast enhancement characteristics were missing in 33%, of patients studied. Postoperative imaging was not always available, especially in group I, and extent of resection was often determined by the neurosurgeon's impression. Although neurosurgeons' impressions are notoriously unreliable, 29 results from our previous series report excellent accuracy of Mayo Clinic neurosurgeons' estimation of tumor volume resected and prognosis, which was again confirmed in this study. 6 Because Mayo Clinic is a tertiary care referral center, a total of 218 patients were lost to follow-up. Genetic testing for 1p/19q status was not routinely performed on specimens before 2002. Consequently, IDH-1 status and 1p/19q status are largely unreported for this patient population.
Conclusion
In summary, this retrospective analysis of a large cohort of adult patients with LGG treated at Mayo Clinic since 1960 reveals improving OS but unchanged PFS over time. More patients in the modern cohort are receiving a diagnosis of oligodendroglioma, and the rate of successful GTR/rSTR has increased. Risk factors typically associated with prognosis (age, tumor size, histology, and symptoms at presentation) are also associated with the extent of neurosurgical resection. The use of PORT has decreased and is presently being used to treat patients at high risk of progression.
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